Critical Review: Exelixis (EXEL) vs. National Research (NRCIB)

Exelixis (NASDAQ: EXEL) and National Research (NASDAQ:NRCIB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Profitability

This table compares Exelixis and National Research’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exelixis 43.39% 77.39% 40.62%
National Research 19.52% 27.45% 19.09%

Insider & Institutional Ownership

80.2% of Exelixis shares are owned by institutional investors. Comparatively, 2.5% of National Research shares are owned by institutional investors. 4.8% of Exelixis shares are owned by insiders. Comparatively, 39.1% of National Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Exelixis and National Research’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Exelixis $452.48 million 14.16 $154.22 million $0.51 42.31
National Research $117.56 million 11.05 $22.94 million N/A N/A

Exelixis has higher revenue and earnings than National Research.

Analyst Ratings

This is a summary of recent ratings for Exelixis and National Research, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis 0 3 9 0 2.75
National Research 0 0 0 0 N/A

Exelixis currently has a consensus target price of $33.56, indicating a potential upside of 55.49%. Given Exelixis’ higher probable upside, analysts clearly believe Exelixis is more favorable than National Research.

Dividends

National Research pays an annual dividend of $2.40 per share and has a dividend yield of 4.5%. Exelixis does not pay a dividend.

Risk and Volatility

Exelixis has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Summary

Exelixis beats National Research on 10 of the 13 factors compared between the two stocks.

Exelixis Company Profile

Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience, satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The company offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. It also provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. The company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, increase patient satisfaction and support safe care transitions; and risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. It provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems and post-acute providers, such as home health, long term care, hospice, and payer organizations. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply